P53-DEPENDENT APOPTOSIS MODULATES THE CYTOTOXICITY OF ANTICANCER AGENTS

被引:2962
作者
LOWE, SW
RULEY, HE
JACKS, T
HOUSMAN, DE
机构
[1] MIT,DEPT BIOL,CAMBRIDGE,MA 02139
[2] VANDERBILT UNIV,MED CTR,SCH MED,DEPT MICROBIOL & IMMUNOL,NASHVILLE,TN 37232
关键词
D O I
10.1016/0092-8674(93)90719-7
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Although the primary cellular targets of many anticancer agents have been identified, less is known about the processes leading to the selective cell death of cancer cells or the molecular basis of drug resistance. p53-deficient mouse embryonic fibroblasts were used to examine systematically the requirement for p53 in cellular sensitivity and resistance to a diverse group of anticancer agents. These results demonstrate that an oncogene, specifically the adenovirus E1A gene, can sensitize fibroblasts to apoptosis induced by ionizing radiation, 5-fluorouracil, etoposide, and adriamycin. Furthermore, the p53 tumor suppressor is required for efficient execution of the death program. These data reinforce the notion that the cytotoxic action of many anticancer agents involves processes subsequent to the interaction between drug and cellular target and indicate that divergent stimuli can activate a common cell death program. Consequently, the involvement of p53 in the apoptotic response suggests a mechanism whereby tumor cells can acquire cross-resistance to anticancer agents.
引用
收藏
页码:957 / 967
页数:11
相关论文
共 61 条
[21]   P53 ALTERATION IS A COMMON EVENT IN THE SPONTANEOUS IMMORTALIZATION OF PRIMARY BALB/C MURINE EMBRYO FIBROBLASTS [J].
HARVEY, DM ;
LEVINE, AJ .
GENES & DEVELOPMENT, 1991, 5 (12B) :2375-2385
[22]   TIMING AND ROLE OF P53 GENE MUTATION IN THE RECURRENCE OF GLIOMA [J].
HAYASHI, Y ;
YAMASHITA, J ;
YAMAGUCHI, K .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 180 (02) :1145-1150
[23]  
HEIMDAL K, 1993, NEW BIOL, V3, P825
[24]   P53 MUTATIONS IN HUMAN CANCERS [J].
HOLLSTEIN, M ;
SIDRANSKY, D ;
VOGELSTEIN, B ;
HARRIS, CC .
SCIENCE, 1991, 253 (5015) :49-53
[25]  
HORIO Y, 1993, CANCER RES, V53, P1
[26]  
ISAACS WB, 1991, CANCER RES, V51, P4716
[27]   PROGNOSTIC IMPLICATIONS OF P53 PROTEIN, EPIDERMAL GROWTH-FACTOR RECEPTOR, AND KI-67 LABELING IN BRAIN-TUMORS [J].
JAROS, E ;
PERRY, RH ;
ADAM, L ;
KELLY, PJ ;
CRAWFORD, PJ ;
KALBAG, RM ;
MENDELOW, AD ;
SENGUPTA, RP ;
PEARSON, ADJ .
BRITISH JOURNAL OF CANCER, 1992, 66 (02) :373-385
[28]  
JONVEAUX P, 1991, LEUKEMIA, V5, P839
[29]   A MAMMALIAN-CELL CYCLE CHECKPOINT PATHWAY UTILIZING P53 AND GADD45 IS DEFECTIVE IN ATAXIA-TELANGIECTASIA [J].
KASTAN, MB ;
ZHAN, QM ;
ELDEIRY, WS ;
CARRIER, F ;
JACKS, T ;
WALSH, WV ;
PLUNKETT, BS ;
VOGELSTEIN, B ;
FORNACE, AJ .
CELL, 1992, 71 (04) :587-597
[30]  
KASTAN MB, 1991, CANCER RES, V51, P6304